ACAina Liz Alves Cesar

Aina Liz Alves Cesar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aina Liz Alves Cesar has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost analysis of GenoType® MTBDRplus and GenoType® MTBDRsl at the State Laboratory of São Paulo, Brazil

    by Lida Jouca de Assis Figueredo, Aina Liz Alves César, Lucilaine Ferrazoli, Erica Chimara, Maria Claudia Vater, Suely Conceição Alves da Silva, Afrânio Lineu Kritski, Silvana Spíndola de Miranda

    We aimed to evaluate the costs of GenoType® MTBDRplus and MTBDRsl incurred during the diagnosis of first- and second-line drug-resistant tuberculosis (TB) in São Paulo, Brazil.


  • Open Access

    Evaluation of mesalazine polymeric conjugate in the treatment of actinic proctitis in rats

    by Vinícius Rodrigues Taranto Nunes, Paula Vieira Teixeira Vidigal, Márcio Tadeu Pereira, Luís Carlos Duarte Ladeira, Marcelo Vidigal Caliari, Fabrício Marcus Silva Oliveira, Aina Liz Alves Cesar, André Augusto Gomes Faraco, Rafael Calvão Barbuto, Ivana Duval-Araujo

    The present study aimed at testing a new formulation of mesalazine linked to chondroitin sulfate and its components alone in the treatment of actinic proctitis in rats. Forty-seven female Wistar rats were submitted to pelvic radiation and divided into eight groups: control A, mesalazine A, chondroitin A, and conjugate A, gavage of the according substance two weeks after irradiation and sacrifice three weeks after oral treatment; control C, mesalazine C, chondroitin C, and conjugate C, sacrifice six weeks after oral treatment. The rectum was submitted to histological characterization for each of the findings: inflammatory infiltrate, epithelial degeneration, mucosal necrosis, and fibrosis. The inflammatory infiltrate was more intense in chondroitin A, mesalazine A, and conjugate C. The collagen deposition was less intense in chondroitin A, and mesalazine A, and more intense in control C. Mesalazine and chondroitin alone were efficacious in inducing a delayed inflammatory response, hence reducing the late fibrosis. The conjugate was able to induce an ever more delayed inflammatory response.

  • New antiglaucomatous agent for the treatment of open angle glaucoma: Polymeric inserts for drug release and in vitro and in vivo study

    by Aina Liz A. Cesar, Larissa Caldeira Navarro, Rachel Oliveira Castilho, Gisele Assis Castro Goulart, Giselle Foureaux, Anderson J. Ferreira, Sebastião Cronemberger, André Augusto Gomes Faraco

    A benzamidine derivative from diminazene was tested for a novel activity: treatment of primary open‐angle glaucoma. This drug was incorporated into mucoadhesive polymeric inserts prepared using chitosan (Chs) and chondroitin sulfate (CS). Of current interest is the mucoadhesion, which increases the contact time with the ocular surface, resulting in improved bioavailability; also, the inserts are made to act as a prolonged release system. In the present work the inserts were prepared by the solvent casting method using different polymeric proportions (30:70, 50:50, 75:25 % w/w Chs:CS and 100 % Chs). Thermal analysis and infrared spectroscopy both demonstrated physical dispersion of the active drug. The most promising was the 50:50 % Chs:CS which demonstrated that it was not fragile and has an in vitro release profile of up to 180 minutes. In addition, it presented greater adhesion strength in relation to the other formulations. These physicochemical results corroborate the in vivo tests performed. In this sense, we also demonstrated that the treatment with the 50:50 % insert can control the intraocular pressure (IOP) for at least three weeks and prevents damage to the retinal ganglion cells (RGCs) compared to the placebo insert. Thus, this indicates thus that the new drug is quite viable and promising in glaucoma treatment.


  • Use of chitosan as pharmaceutical excipient in ocular drug delivery systems: Sterilization and pharmacokinetics

    by Juçara R. Franca, Leonardo L. Fuscaldi, Tatiana G. Ribeiro, Giselle Foureaux, Aina L. A. Cesar, Rachel O. Castilho, Sebastião Cronemberger, Anderson J. Ferreira, Simone O. A. Fernandes, Valbert N. Cardoso, et al.

    The use of chitosan as a pharmaceutical excipient in the ocular field is already established. Nevertheless, some aspects related to its ocular administration, such as sterilization and excipient's pharmacokinetics, remain unclear. So, in this study, we evaluated those two relevant aspects, related to chitosan administration in eye. We used chitosan‐based ocular inserts (CI) as formulation model. CI were produced by solvent/casting method and sterilized by saturated steam. Sterilization was confirmed by direct inoculation of inserts in suitable microbiological growth media. Physicochemical characterization of inserts before and after sterilization was performed. Results suggested that, although steam sterilization changed the arrangement of the matrix, the heat and the humidity did not modify the structure of the main polymeric chain. Pharmacokinetics of CI radiolabeled with technetium‐99m (99mTc) was assessed by scintigraphic images and ex vivo biodistribution study, after ocular administration in male Wistar rats. Scintigraphic and images analysis and ex vivo biodistribution study showed that the insert remained mainly in the eye until 6 hr after administration and its degradation products began to migrate to the abdominal cavity after 18 hr. Together, these data represent an important step forward the manufacturing and the clinical application of CI in the ophthalmic field.


  • Open Access

    Development and validation of analytical method by HPLC-DAD for determination of vasodilator active in pharmaceutical ophthalmic forms

    by Aina Liz Alves Cesar, Larissa Caldeira Navarro, Alaíde de Matos Silva, Rachel Oliveira Castilho, Gisele Assis Castro Goulart, Giselle Foureaux Heida, Anderson José Ferreira, Sebastião Cronemberger, André Augusto Gomes Faraco

    4-Aminobenzamidine dihydrochloride (4-AD) is one of the degradation products of diminazene aceturate, which have been demonstrating anti-glaucoma potential. As glaucoma is the second leading cause of blindness worldwide, it is relevant to study new therapeutic alternatives, for example, 4-AD carried in polymeric inserts of prolonged release. The present work aims to develop and validate an analytical method for the quantification of 4-AD. An HPLC with UV-Vis detector was used, using a wavelength of 290 ƞm and an ACE® C18 column (125x4.6 mm, 5 μm) mobile phase consisting of phosphate (pH 7.4 ) and triethylamine in the concentration of 0.03% (v / v), in isocratic mode and flow of 1.0 mL / min. . The retention time for 4-AD was 3.2 minutes. The method was developed and validated in accordance with the recommendations of the Resolution of the Collegiate Board (RDC) No. 166 of 2017 of ANVISA, of the Brazilian Pharmacopoeia 5th edition and of the ICH quality guides. The linearity range was established between the concentrations of 5 and 25 μg / mL (r2), the accuracy, repeatability, intermediate precision tests showed a relative standard deviation less than or equal to 5%, in addition the method was also considered selective, exact and robust, pH being its critical factor. Therefore, the HPLC analysis method is robust and can be used to quantify the substance 4-AD in pharmaceutical forms for ocular application.

  • New mesalamine polymeric conjugate for controlled release: Preparation, characterization and biodistribution study

    by Aina L.A. Cesar, Fernanda A. Abrantes, Luana Farah, Rachel O. Castilho, Valbert Cardoso, Simone O. Fernandes, Ivana D. Araújo, André A.G. Faraco